Who Owns Xencor Company?

Who Owns Xencor?

Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company founded in 1997. Headquartered in Pasadena, California, it focuses on developing engineered monoclonal antibodies and protein therapeutics using its proprietary XmAb technology platform.

Understanding the ownership of Xencor is key to grasping its strategic direction and accountability. The company's market capitalization hovers around $628.44 million to $681 million as of July 2025, with approximately 71.2 million shares outstanding, classifying it as a small-cap entity in the biotechnology sector.

The ownership of Xencor is primarily distributed among institutional investors, mutual funds, and individual shareholders. As of recent filings, major institutional holders include Vanguard Group Inc., BlackRock Inc., and Renaissance Technologies LLC. These entities collectively manage a significant portion of the company's outstanding shares, influencing its governance and strategic decisions. The founders, Dr. Bassil Dahiyat and Dr. Stephen Mayo, also retain ownership stakes, reflecting their continued commitment to the company's vision. The company's innovative approach is evident in its Xencor BCG Matrix, showcasing its pipeline development.

Xencor was co-founded in 1997 by Dr. Bassil Dahiyat and Dr. Stephen Mayo, with Dr. Dahiyat continuing to lead as President and CEO. Their vision for engineering antibodies to treat diseases has been central to the company's growth and the development of its proprietary XmAb® technology.

Founding Team

Xencor was established in 1997 by Dr. Bassil Dahiyat and Dr. Stephen Mayo. Dr. Dahiyat has remained at the helm as President and CEO since the company's inception.

Core Technology

Dr. Bassil Dahiyat is a co-inventor of Xencor's foundational XmAb® technology. This technology is integral to the company's pipeline and its approach to drug development.

Early Ownership Details

Specifics on the initial equity distribution or the exact number of shares held by the founders at the company's start are not publicly detailed. However, Dr. Dahiyat's ongoing leadership and role in technology development suggest a significant foundational stake.

Initial Funding Landscape

While detailed information on early angel investors or friends and family funding rounds is not readily available, the company was previously supported by venture capital before transitioning to public ownership.

Founder's Influence

Dr. Dahiyat's continuous role as CEO and his co-invention of the core XmAb® technology underscore his substantial influence on Xencor's strategic direction and ownership structure.

Company Trajectory

The company's founding vision, focused on antibody engineering for disease treatment, has been consistently driven by the advancement and application of its proprietary technology.

The early stages of Xencor's existence involved securing funding from venture capital firms, a common pathway for biotechnology companies aiming to develop complex scientific platforms and drug candidates. While the specifics of early agreements like vesting schedules or founder exit strategies are not publicly disclosed, the company's progression from a privately held, venture-backed entity to a publicly traded company indicates significant milestones in its ownership history. Understanding the Revenue Streams & Business Model of Xencor provides further context on how its ownership structure supports its operational goals.

Key Aspects of Early Xencor Ownership

The foundational ownership of Xencor is rooted in its co-founders, Dr. Bassil Dahiyat and Dr. Stephen Mayo, who established the company in 1997. Dr. Dahiyat's ongoing leadership as CEO highlights his significant stake and influence.

• Co-founders: Dr. Bassil Dahiyat and Dr. Stephen Mayo
• CEO and President: Dr. Bassil Dahiyat
• Proprietary Technology: XmAb®
• Early Funding: Venture capital backing
• Company Status: Formerly venture capital-backed, now publicly held

Xencor's journey from a privately held, venture-backed entity to a publicly traded company on The NASDAQ Global Market marked a significant shift in its ownership structure. This transition, initiated by its IPO in December 2013, opened the door for a broader base of investors to hold stakes in the company.

As of mid-2025, Xencor's ownership is diverse, reflecting its status as a publicly traded biotechnology firm. Institutional investors represent a substantial portion of Xencor stock ownership, with their holdings indicating significant confidence in the company's drug development pipeline and Growth Strategy of Xencor. Individual insiders, including key members of the Xencor leadership and Xencor executive team, also maintain stakes, though typically at lower percentages compared to institutional entities. These stakeholders, including the Xencor board of directors, play a role in shaping the company's strategic direction and governance.

Key Stakeholders in Xencor

Understanding Xencor's ownership breakdown reveals the influence of various investor types. Major institutional investors and individual insiders are key players in the Xencor company structure.

• The Vanguard Group is a significant institutional investor, holding approximately 12.91% of Xencor's outstanding shares as of June 30, 2025.
• Insider ownership, including Xencor CEO Bassil I. Dahiyat and Chief Scientific Officer John R. Desjarlais, contributes to the overall Xencor company ownership.
• Recent stock transactions by directors indicate active management of personal holdings, influencing Xencor stock ownership dynamics.
• The high percentage of institutional ownership suggests that many Xencor shareholders are large investment firms and funds.

As of July 2025, Xencor's Board of Directors comprises individuals with extensive experience in biotechnology and drug development, guiding the company's strategic direction. Key members include co-founder and CEO Dr. Bassil I. Dahiyat, who has been with the company since its inception.

Xencor operates under a standard voting structure for publicly traded companies, where common stock typically follows a one-share-one-vote principle. This means that voting power is generally proportional to the number of shares held by each stockholder. Public filings, such as the DEF 14A proxy statement from April 24, 2024, confirm that stockholders of record as of April 15, 2024, were eligible to vote at the 2024 Annual Meeting. There is no public information indicating the existence of dual-class shares or other special voting rights that would concentrate control beyond proportional ownership, suggesting a straightforward approach to Xencor company ownership and governance.

Understanding Xencor's Shareholder Structure

The voting power at Xencor is primarily determined by share ownership, reflecting a commitment to equitable shareholder influence. Recent transactions by board members highlight ongoing engagement with the company's financial activities.

• Voting power aligns with share ownership.
• No evidence of preferential voting rights.
• Routine insider transactions are publicly reported.
• No major governance disputes have been publicly disclosed.
• Understanding Target Market of Xencor can provide context on company strategy.

Over the past few years, Xencor has seen shifts in its ownership landscape, influenced by public offerings and evolving leadership. These developments provide insight into who owns Xencor and its strategic trajectory.

Xencor's ownership structure is characterized by a substantial presence of institutional investors, with their stake exceeding 100% as of July 31, 2025. This indicates a significant portion of the company's stock is held by various funds and financial institutions. Insider ownership, on the other hand, remains a smaller fraction, ranging from 0.9% to 5.23%. Over the last two years, there has been notable insider selling, with executives and directors selling a combined total of 334,540 shares, amounting to over $7.19 million. This activity, alongside leadership changes such as Nancy Valente's transition to a senior advisory role in June 2025 and Raymond Deshaies' appointment to the Board of Directors in July 2025, shapes the company's governance and strategic direction. The company's financial health, projected to end 2025 with $535 million to $585 million in cash and equivalents, supports its ongoing research and development efforts and partnerships, rather than immediate major ownership restructuring.

Institutional Investor Influence

Institutional investors hold a significant portion of Xencor's stock. This ownership trend reflects confidence in the company's long-term prospects within the biopharmaceutical sector.

Insider Transactions and Leadership

While insider ownership is modest, recent selling activity and board changes are key factors in understanding Xencor company ownership. These movements can signal shifts in management's outlook.

Capital Infusion and Future Funding

The September 2024 public offering provided substantial capital, bolstering Xencor's financial standing. This funding is crucial for continued drug development and research, impacting Xencor's investment strategy.

Strategic Outlook and Ownership Trends

Xencor's financial guidance suggests a focus on internal growth and partnerships. This approach indicates that major ownership shifts like acquisitions are not the immediate focus, aligning with the company's Brief History of Xencor.